View Single Post
Old 11-09-2006, 10:10 AM   #2
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
continued...

"The binding of Srcasm to Fyn regulates Fyn's persistence in the cell," says Seykora. "If Srcasm is low, Fyn persists longer and sends more growth-promoting signals."

Reversing Tumors
Eventually, Srcasm might play a role in targeted gene therapies for cancers that are triggered by activated Src kinases. Such a therapy would likely use an adenovirus to carry a gene that codes for Srcasm into skin cells to increase Srcasm production, as used in some other gene therapy treatments. Initially, clinicians may try this method on oral cavity and skin cancers.

Next, the Penn researchers will determine whether Srcasm can actually reverse tumor formation in skin. Seykora's team has already prepared an adenovirus and mice with the tumor-forming Src kinases expressed in their skin. Within six months, the group expects to know whether Srcasm can decrease squamous cell carcinoma formation in skin, mentions Seykora.

###

This research was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Other co-authors in addition to Seykora are Weijie Li, Christine Marshall, Lijuan Mei, and Joel Gelfand, all from Penn.
Lani is offline   Reply With Quote